From targeted cancer treatments to genomic diagnostics and AI-led drug discovery, UK precision medicine companies are changing how treatments are developed and matched to patients.
Precision medicine tailors treatment to the biology of individual patients rather than to the average. Using Beauhurst data, we’ve ranked 100 UK-headquartered precision medicine companies by the total equity funding they have raised.
Together, the companies in our wider analysis have raised £13.1b across 657 equity rounds. They raised £2.16b in the first nine months of 2026, the second highest annual total on record.
This is not a ranking of the UK’s largest pharmaceutical companies. Instead, it shows which businesses developing targeted therapies, diagnostics, and drug discovery platforms have attracted the most equity investment.
The UK precision medicine sector
Precision medicine uses genetic, molecular, and clinical data to match treatments to the patients most likely to benefit from them.
In practice that spans drug developers designing therapies for specific genetic targets, diagnostics companies identifying which patients those therapies suit, and the platforms used to find the targets in the first place.
The companies in our analysis fall into three broad groups:
- Targeted therapeutics: Drug developers working on antibodies, cell and gene therapies, and small molecules aimed at specific biological pathways.
- Diagnostics and genomics: Blood tests, sequencing, and genome analysis used to detect disease and guide treatment.
- AI drug discovery and research tools: Machine learning platforms and laboratory technologies used to identify and validate new drug targets.
Pharmaceuticals is a secondary tag on 91 of the 109 companies tracked, clinical research on 67, and biotechnology on 64.
There are 109 companies in the wider cohort today, compared with 42 at the end of 2015. That is growth of 160% over the decade.
The cohort is weighted towards companies still in development. Some 46 are at venture stage and 24 at growth stage, with 16 at seed and 13 established. Nine have exited and one is recorded as dead.
New company formation has slowed sharply, from 11 companies founded in 2021 to one in 2024 and two in 2025.
Precision medicine funding in the UK
Across the companies in our analysis, total equity funding stands at £13.1b across 657 equity rounds.
Isomorphic Labs leads the ranking with £2.02b. The DeepMind spinout raised a $2.1b Series B in May 2026 to fund its AI drug design platform.
Autolus follows with £1.06b in T-cell immunotherapy, ahead of Oxford Nanopore Technologies (£1.01b) in DNA sequencing, Bicycle Therapeutics (£673m), and Silence Therapeutics (£421m).
Concentration is moderate for a sector of this size. Isomorphic Labs accounts for 15% of the total, the top five for 39%, and the top 10 for 51%. Excluding Isomorphic Labs, the remaining companies have raised £11.1b.
Revenue remains limited, as it tends to be in drug development. Oxford Nanopore reported £224m in its latest accounts, followed by OXB at £169m and Blue Earth Diagnostics at £150m, while most of the cohort is pre-revenue.
Who invests in UK precision medicine companies?
This is the most university-linked investor base of any ranking in our Top 100 series.
IP Group is the most active backer with 28 rounds, followed by Cambridge Innovation Capital with 24, Syncona Partners with 18, and Oxford Science Enterprises and SV Health Investors with 17 each. Cambridge Enterprise Ventures and Touchstone Innovations have each backed 15.
Every one of those is a specialist technology transfer or life sciences investor, and several exist specifically to commercialise university research.
By value the picture shifts to international capital, led by GV at £2.25b and Temasek at £2.08b, with Alphabet, Thrive Capital, MGX, and the UK Government’s Sovereign AI Fund all appearing through the largest recent rounds.
Where are the UK’s precision medicine companies?
Precision medicine is more evenly spread than most sectors we have ranked, and less concentrated in London.
The South East leads, built around Oxford, with companies including Oxford Nanopore, OXB, Genomics, Grey Wolf Therapeutics, and Nucleome Therapeutics.
The East of England follows, centred on Cambridge, with Bicycle Therapeutics, Artios Pharma, Storm Therapeutics, Nuclera, and Spur Therapeutics among them.
London accounts for a smaller share than in any technology ranking, and the cohort also reaches Wales, Scotland, the North West, the North East, and Yorkshire and the Humber.
